Listed

Theriva Biologics, Inc.

TOVXNYSECIK 894158HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$3.3m, Q2 FY2026
Net income−$3.2m, Q2 FY2026
Theriva Biologics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.3Revenue, Q1 FY2026, three months to 2026-03-31$300.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001104659-26-093786. Derived: 6-month figure less the 3-month figure.Report this figure
Research and development$m4.0Research and development, Q3 FY2023, three months to 2023-09-30$4.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figure4.2Research and development, Q4 FY2023, three months to 2023-12-31$4.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-06, accession 0001410578-25-000285. Derived: 12-month figure less the 9-month figure.Report this figure3.5Research and development, Q1 FY2024, three months to 2024-03-31$3.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure3.0Research and development, Q2 FY2024, three months to 2024-06-30$3.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0001410578-25-001654.Report this figure2.7Research and development, Q3 FY2024, three months to 2024-09-30$2.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure2.9Research and development, Q4 FY2024, three months to 2024-12-31$2.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001104659-26-026767. Derived: 12-month figure less the 9-month figure.Report this figure3.0Research and development, Q1 FY2025, three months to 2025-03-31$3.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure2.0Research and development, Q2 FY2025, three months to 2025-06-30$2.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure2.6Research and development, Q3 FY2025, three months to 2025-09-30$2.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure1.1Research and development, Q4 FY2025, three months to 2025-12-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001104659-26-026767. Derived: 12-month figure less the 9-month figure.Report this figure0.4Research and development, Q1 FY2026, three months to 2026-03-31$355.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure1.3Research and development, Q2 FY2026, three months to 2026-06-30$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure
Operating income$m(4.2)Operating income, Q3 FY2023, three months to 2023-09-30−$4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figure(6.2)Operating income, Q4 FY2023, three months to 2023-12-31−$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-06, accession 0001410578-25-000285. Derived: 12-month figure less the 9-month figure.Report this figure(5.4)Operating income, Q1 FY2024, three months to 2024-03-31−$5.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure(8.5)Operating income, Q2 FY2024, three months to 2024-06-30−$8.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0001410578-25-001654.Report this figure(7.9)Operating income, Q3 FY2024, three months to 2024-09-30−$7.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure(4.6)Operating income, Q4 FY2024, three months to 2024-12-31−$4.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001104659-26-026767. Derived: 12-month figure less the 9-month figure.Report this figure(4.4)Operating income, Q1 FY2025, three months to 2025-03-31−$4.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure(13.1)Operating income, Q2 FY2025, three months to 2025-06-30−$13.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure(4.4)Operating income, Q3 FY2025, three months to 2025-09-30−$4.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure(2.1)Operating income, Q4 FY2025, three months to 2025-12-31−$2.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001104659-26-026767. Derived: 12-month figure less the 9-month figure.Report this figure(2.1)Operating income, Q1 FY2026, three months to 2026-03-31−$2.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure(3.3)Operating income, Q2 FY2026, three months to 2026-06-30−$3.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure
Income tax$m(0.5)Income tax, Q3 FY2023, three months to 2023-09-30−$527.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figure(0.4)Income tax, Q4 FY2023, three months to 2023-12-31−$424.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-06, accession 0001410578-25-000285. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(3.3)Net income, Q3 FY2023, three months to 2023-09-30−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2023-11-13, accession 0001410578-23-002348.Report this figure(5.5)Net income, Q4 FY2023, three months to 2023-12-31−$5.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-25, accession 0001410578-24-000293. Derived: 12-month figure less the 9-month figure.Report this figure(5.2)Net income, Q1 FY2024, three months to 2024-03-31−$5.2m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure(8.3)Net income, Q2 FY2024, three months to 2024-06-30−$8.3m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure(7.7)Net income, Q3 FY2024, three months to 2024-09-30−$7.7m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure(4.4)Net income, Q4 FY2024, three months to 2024-12-31−$4.4m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-12, accession 0001104659-26-026767. Derived: 12-month figure less the 9-month figure.Report this figure(4.3)Net income, Q1 FY2025, three months to 2025-03-31−$4.3m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure(13.1)Net income, Q2 FY2025, three months to 2025-06-30−$13.1m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure(4.4)Net income, Q3 FY2025, three months to 2025-09-30−$4.4m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure(2.0)Net income, Q4 FY2025, three months to 2025-12-31−$2.0m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-12, accession 0001104659-26-026767. Derived: 12-month figure less the 9-month figure.Report this figure(2.0)Net income, Q1 FY2026, three months to 2026-03-31−$2.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure(3.2)Net income, Q2 FY2026, three months to 2026-06-30−$3.2m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure
Diluted EPS$ per share(4.85)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$4.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figurenot reported(7.53)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$7.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure(10.72)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$10.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0001410578-25-001654.Report this figure(6.81)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$6.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figurenot reported(1.55)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure(1.93)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure(0.45)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figurenot reported(0.05)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure(0.07)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure
Basic EPS$ per share(4.85)Basic EPS, Q3 FY2023, three months to 2023-09-30−$4.85 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figurenot reported(7.53)Basic EPS, Q1 FY2024, three months to 2024-03-31−$7.53 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure(10.72)Basic EPS, Q2 FY2024, three months to 2024-06-30−$10.72 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001410578-25-001654.Report this figure(6.81)Basic EPS, Q3 FY2024, three months to 2024-09-30−$6.81 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figurenot reported(1.55)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure(1.93)Basic EPS, Q2 FY2025, three months to 2025-06-30−$1.93 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure(0.45)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figurenot reported(0.05)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure(0.07)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure

Balance sheet

Cash and equivalents$11.3m, Q2 FY2026
Long-term debt$1.7m, FY2025
Shareholders' equity$12.2m, Q2 FY2026
Theriva Biologics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m31.2Cash and equivalents, Q3 FY2023, at 2023-09-30$31.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figure23.2Cash and equivalents, FY2023, at 2023-12-31$23.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-06, accession 0001410578-25-000285.Report this figure18.3Cash and equivalents, Q1 FY2024, at 2024-03-31$18.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure16.6Cash and equivalents, Q2 FY2024, at 2024-06-30$16.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001410578-25-001654.Report this figure16.4Cash and equivalents, Q3 FY2024, at 2024-09-30$16.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure11.6Cash and equivalents, FY2024, at 2024-12-31$11.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-12, accession 0001104659-26-026767.Report this figure10.0Cash and equivalents, Q1 FY2025, at 2025-03-31$10.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure12.1Cash and equivalents, Q2 FY2025, at 2025-06-30$12.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure7.5Cash and equivalents, Q3 FY2025, at 2025-09-30$7.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure13.1Cash and equivalents, FY2025, at 2025-12-31$13.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure14.4Cash and equivalents, Q1 FY2026, at 2026-03-31$14.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure11.3Cash and equivalents, Q2 FY2026, at 2026-06-30$11.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure
Current assets$m34.8Current assets, Q3 FY2023, at 2023-09-30$34.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0001410578-23-002348.Report this figure27.4Current assets, FY2023, at 2023-12-31$27.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-06, accession 0001410578-25-000285.Report this figure21.7Current assets, Q1 FY2024, at 2024-03-31$21.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001410578-24-000601.Report this figure19.7Current assets, Q2 FY2024, at 2024-06-30$19.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001410578-24-001342.Report this figure19.5Current assets, Q3 FY2024, at 2024-09-30$19.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figure16.3Current assets, FY2024, at 2024-12-31$16.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-12, accession 0001104659-26-026767.Report this figure12.5Current assets, Q1 FY2025, at 2025-03-31$12.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure14.7Current assets, Q2 FY2025, at 2025-06-30$14.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0001410578-25-001654.Report this figure9.9Current assets, Q3 FY2025, at 2025-09-30$9.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure17.5Current assets, FY2025, at 2025-12-31$17.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure16.8Current assets, Q1 FY2026, at 2026-03-31$16.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure13.7Current assets, Q2 FY2026, at 2026-06-30$13.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure
Total assets$m61.5Total assets, Q3 FY2023, at 2023-09-30$61.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0001410578-23-002348.Report this figure55.2Total assets, FY2023, at 2023-12-31$55.2m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-06, accession 0001410578-25-000285.Report this figure48.7Total assets, Q1 FY2024, at 2024-03-31$48.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001410578-24-000601.Report this figure42.4Total assets, Q2 FY2024, at 2024-06-30$42.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001410578-24-001342.Report this figure40.1Total assets, Q3 FY2024, at 2024-09-30$40.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figure35.4Total assets, FY2024, at 2024-12-31$35.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-12, accession 0001104659-26-026767.Report this figure32.2Total assets, Q1 FY2025, at 2025-03-31$32.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure35.8Total assets, Q2 FY2025, at 2025-06-30$35.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0001410578-25-001654.Report this figure30.8Total assets, Q3 FY2025, at 2025-09-30$30.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure38.2Total assets, FY2025, at 2025-12-31$38.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure38.2Total assets, Q1 FY2026, at 2026-03-31$38.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure34.9Total assets, Q2 FY2026, at 2026-06-30$34.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure
Current liabilities$m8.7Current liabilities, Q3 FY2023, at 2023-09-30$8.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0001410578-23-002348.Report this figure6.7Current liabilities, FY2023, at 2023-12-31$6.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-06, accession 0001410578-25-000285.Report this figure6.0Current liabilities, Q1 FY2024, at 2024-03-31$6.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001410578-24-000601.Report this figure6.8Current liabilities, Q2 FY2024, at 2024-06-30$6.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001410578-24-001342.Report this figure7.3Current liabilities, Q3 FY2024, at 2024-09-30$7.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figure7.6Current liabilities, FY2024, at 2024-12-31$7.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-12, accession 0001104659-26-026767.Report this figure8.1Current liabilities, Q1 FY2025, at 2025-03-31$8.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure12.4Current liabilities, Q2 FY2025, at 2025-06-30$12.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0001410578-25-001654.Report this figure11.0Current liabilities, Q3 FY2025, at 2025-09-30$11.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure10.0Current liabilities, FY2025, at 2025-12-31$10.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure10.3Current liabilities, Q1 FY2026, at 2026-03-31$10.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure12.1Current liabilities, Q2 FY2026, at 2026-06-30$12.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure
Total liabilities$m17.7Total liabilities, Q3 FY2023, at 2023-09-30$17.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0001410578-23-002348.Report this figure15.5Total liabilities, FY2023, at 2023-12-31$15.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-06, accession 0001410578-25-000285.Report this figure14.6Total liabilities, Q1 FY2024, at 2024-03-31$14.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0001410578-24-000601.Report this figure14.7Total liabilities, Q2 FY2024, at 2024-06-30$14.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001410578-24-001342.Report this figure15.5Total liabilities, Q3 FY2024, at 2024-09-30$15.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figure16.3Total liabilities, FY2024, at 2024-12-31$16.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-12, accession 0001104659-26-026767.Report this figure16.7Total liabilities, Q1 FY2025, at 2025-03-31$16.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure25.2Total liabilities, Q2 FY2025, at 2025-06-30$25.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0001410578-25-001654.Report this figure24.1Total liabilities, Q3 FY2025, at 2025-09-30$24.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure22.9Total liabilities, FY2025, at 2025-12-31$22.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure22.8Total liabilities, Q1 FY2026, at 2026-03-31$22.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure22.7Total liabilities, Q2 FY2026, at 2026-06-30$22.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure
Long-term debt$m0.2Long-term debt, Q3 FY2023, at 2023-09-30$150.0k. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2023-11-13, accession 0001410578-23-002348.Report this figure0.2Long-term debt, FY2023, at 2023-12-31$162.0k. XBRL concept us-gaap:LongTermDebt. 10-K filed 2025-03-06, accession 0001410578-25-000285.Report this figurenot reportednot reportednot reported0.1Long-term debt, FY2024, at 2024-12-31$92.0k. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-03-12, accession 0001104659-26-026767.Report this figurenot reportednot reportednot reported1.7Long-term debt, FY2025, at 2025-12-31$1.7m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-03-12, accession 0001104659-26-026767.Report this figurenot reportednot reported
Short-term borrowings$m0.1Short-term borrowings, Q3 FY2023, at 2023-09-30$65.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2023-11-13, accession 0001410578-23-002348.Report this figure0.1Short-term borrowings, FY2023, at 2023-12-31$63.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-K filed 2024-03-25, accession 0001410578-24-000293.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m41.2Shareholders' equity, Q3 FY2023, at 2023-09-30$41.1m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figure37.0Shareholders' equity, FY2023, at 2023-12-31$37.0m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-K filed 2026-03-12, accession 0001104659-26-026767.Report this figure31.4Shareholders' equity, Q1 FY2024, at 2024-03-31$31.4m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure25.9Shareholders' equity, Q2 FY2024, at 2024-06-30$25.9m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure24.6Shareholders' equity, Q3 FY2024, at 2024-09-30$24.6m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure19.1Shareholders' equity, FY2024, at 2024-12-31$19.1m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure15.5Shareholders' equity, Q1 FY2025, at 2025-03-31$15.5m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure10.6Shareholders' equity, Q2 FY2025, at 2025-06-30$10.6m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure6.7Shareholders' equity, Q3 FY2025, at 2025-09-30$6.7m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure15.4Shareholders' equity, FY2025, at 2025-12-31$15.4m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure15.4Shareholders' equity, Q1 FY2026, at 2026-03-31$15.4m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure12.2Shareholders' equity, Q2 FY2026, at 2026-06-30$12.2m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure

Cash flow

Operating cash flow−$3.1m, Q2 FY2026
Capital expenditure$0, Q4 FY2025
Theriva Biologics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(2,953)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001410578-24-001850. Derived: 9-month figure less the 6-month figure.Report this figure(6,541)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$6.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-06, accession 0001410578-25-000285. Derived: 12-month figure less the 9-month figure.Report this figure(4,881)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$4.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure(3,452)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0001410578-25-001654. Derived: 6-month figure less the 3-month figure.Report this figure(3,913)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001104659-25-109828. Derived: 9-month figure less the 6-month figure.Report this figure(4,691)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$4.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001104659-26-026767. Derived: 12-month figure less the 9-month figure.Report this figure(4,756)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure(4,712)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$4.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001104659-26-093786. Derived: 6-month figure less the 3-month figure.Report this figure(4,319)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$4.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001104659-25-109828. Derived: 9-month figure less the 6-month figure.Report this figure(2,882)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001104659-26-026767. Derived: 12-month figure less the 9-month figure.Report this figure(2,456)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure(3,085)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001104659-26-093786. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k129Capital expenditure, Q3 FY2023, three months to 2023-09-30$129.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0001410578-24-001850. Derived: 9-month figure less the 6-month figure.Report this figure56.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$56.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-06, accession 0001410578-25-000285. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001104659-25-109828. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001104659-26-026767. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported19.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$19.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001104659-25-109828. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001104659-26-026767. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)45.89m, Q2 FY2026
Theriva Biologics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares15.8Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3015,844,061 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0001410578-23-002348.Report this figure15.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3115,124,061 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001410578-24-000601.Report this figure15.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3015,166,209 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001410578-24-001342.Report this figure0.7Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30681,708 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001410578-24-001850.Report this figure0.7Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31685,923 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-14, accession 0001410578-25-001242.Report this figure0.8Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30775,736 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0001410578-25-001654.Report this figure1.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-301,134,391 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure2.8Diluted shares (weighted), Q1 FY2025, three months to 2025-03-312,782,449 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure6.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-306,752,953 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure9.7Diluted shares (weighted), Q3 FY2025, three months to 2025-09-309,676,521 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001104659-25-109828.Report this figure41.1Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3141,072,725 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001104659-26-055689.Report this figure45.9Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3045,892,668 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure

Shares outstanding: 45.89mShares outstanding, period not labelled, at 2026-08-0745,892,668 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001104659-26-093786.Report this figure at Aug 7, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. Listed shows no prices and gives no investment advice.